ArticleChinese journal of integrative medicine2026
Baicalein Attenuated Recurrent Pregnancy Loss by Inhibiting Ferroptosis via Activation of Nrf2/GPx4 Axis.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic Reprogramming at the Maternal-Fetal Interface: Insights from Decidual Stromal Cells and Trophoblasts in Healthy Pregnancy Versus Recurrent Pregnancy Loss.International journal of molecular sciences · 2026Review
- Asperosaponin VI Ameliorates Spontaneous Abortion by Inhibiting Trophoblast Ferroptosis via the KEAP1/NRF2/GPX4 Axis.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo verify effect of baicalein on recurrent pregnancy loss (RPL) and explore its mechanism via inhibition of ferroptosis.
methodsIn vivo, CBA/J (n=60) mated DBA/2 (n=50) mice were established as RPL group, while CBA/J mated BALB/c (n=10) mice were regarded as control group. Baicalein (10 and 40 mg/kg), ferroptosis inhibitor (ferrostatin-1, 5 mg/kg) and iron chelator (deferoxamine, 1 mg/kg) were administered in the RPL mice model (n=10 per group) from embryonic day 0.5-12.5 (E0.5-E12.5). Pregnancy outcomes and ferroptosis related markers were detected. Lipid peroxidation was assessed by malondialdehyde (MDA) and antioxidant system was determined by glutathione (GSH), glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity. The Fe
resultsBaicalein significantly attenuated fetal loss (P<0.01) and placental damage in RPL mice. Besides, baicalein reduced placental ferroptosis which manifested decreased MDA, iron content, Acyl-CoA synthetase long-chain family protein expression and enhanced GSH and GPx levels (P<0.01) as well as increased protein expressions that were resistant to ferroptosis (GPx4, SLC7A11 and Nrf2, P<0.01 or P<0.05). In vitro, different concentrations of baicalein restored a ferroptosis inducer-erastin induced HTR-8/SVneo cells damage and lipid peroxidation, but GPx4 inhibition diminished the protective effect of baicalein (P<0.01). Additionally, Nrf2 silencing notably decreased GPx4 expression (P<0.01) and abolished baicalein-mediated anti-ferroptosis effect in HTR-8/SVneo cells.
conclusionBaicalein has a protective effect on RPL via inhibiting ferroptosis through Nrf2/GPx4 signaling axis.
Indexed as
Identifiers
41538121What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.